Phase I trial of ATRA-IV and Depakote in patients with advanced solid tumor malignancies. Academic Article uri icon

Overview

abstract

  • Retinoic acid derivatives have shown their greatest benefit in acute promyelocytic leukemia, but have also demonstrated pre-clinical anti-cancer effects in some solid tumors. Histone deacetylase inhibitors, by upregulating gene expression, are able to limit cancer cell proliferation and induce apoptosis. The combination of all-trans retinoic acid (ATRA) and the histone deacetylase inhibitor valproic acid has been previously studied in hematologic malignancies. We conducted a phase I two-step dose escalation trial of the liposomal ATRA analog ATRA-IV and divalproex sodium (Depakote) in nine patients with advanced solid tumors refractory to prior therapy. Side effects attributed to therapy had a severity

publication date

  • May 8, 2010

Research

keywords

  • Antineoplastic Agents
  • Enzyme Inhibitors
  • Neoplasms
  • Salvage Therapy
  • Tretinoin
  • Valproic Acid

Identity

PubMed Central ID

  • PMC3277777

Scopus Document Identifier

  • 79952029974

Digital Object Identifier (DOI)

  • 10.4161/cbt.9.9.11436

PubMed ID

  • 20200483

Additional Document Info

volume

  • 9

issue

  • 9